Skip to main content


Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.

Full Schedule

Full Schedule

  • Thursday, March 30, 2023
  • 7:00 AM – 8:00 AM
    Exhibits and IRC Encore Posters
  • 7:00 AM – 8:00 AM
    Non-CE Symposia: Advances in AML Therapy: Practical Management of a BCL2-Inhibitor
  • 7:00 AM – 8:00 AM
    Non-CE Symposia: Title TBD (AstraZeneca)
  • 8:00 AM – 9:00 AM
    Considerations in Opioid Tapering in Cancer Survivors
  • 8:00 AM – 9:00 AM
    Current Approaches to Manage Mixed Phenotype Acute Leukemia (MPAL): A Recent Patient Case Analysis
  • 8:00 AM – 9:00 AM
    From Blame & Shame We Overcame: Establishing a Multidisciplinary Cancer Medication Safety Committee
  • 8:00 AM – 9:00 AM
    Impact of Payor Driven Treatment Site of Care Initiatives: Balancing Safety, Quality and Cost
  • 8:00 AM – 9:00 AM
    Polatuzumab-vedotin in upfront diffuse large b-cell lymphoma: efficacy versus financial toxicity
  • 8:00 AM – 9:00 AM
    What’s the risk? Update on the safe use of medicines in G6PD deficiency
  • 9:15 AM – 10:30 AM
    HOPA-ASCO Quality Training Program (QTP) 6-month Program Participants: Panel Discussion
  • 10:45 AM – 12:00 PM
    Controversies in Precision Oncology: Interpreting the Grey Areas
  • 10:45 AM – 12:00 PM
    Evolving Landscape of Early Non-Small Cell Lung Cancer
  • 12:00 PM – 1:00 PM
    Non-CE Symposia: Janssen Oncology invites you to learn more about a new treatment option for patients diagnosed with multiple myeloma who are relapsed/refractory and have received >=4 prior lines of therapy.
  • 12:00 PM – 1:00 PM
    Non-CE Symposia: A Treatment Option for Patients with Gastroesophageal Cancers
  • 12:00 PM – 1:00 PM
    Non-CE Symposia: Discussion of BRUKINSA for adult patients with CLL/SLL
  • 12:00 PM – 1:00 PM
    Preparing for a Career in Hematology/Oncology Pharmacy Practice (Non-CE)
  • 12:00 PM – 1:00 PM
    Quality Improvement
  • 12:00 PM – 1:00 PM
    Special Interest Group (SIG) Networking Luncheon
  • 12:00 PM – 1:00 PM
    What's the Scoop with the Board of Directors?
  • 12:00 PM – 2:00 PM
    Poster Session - Trainee Research (Odd #)
  • 2:15 PM – 3:15 PM
    John G. Kuhn Keynote Address: I’m Not Limping. That’s Swagger! (Non-CE)
  • 3:30 PM – 4:45 PM
    Optimizing Decision-Making for Treatment in Metastatic Renal Cell Carcinoma (mRCC): Balancing Evidence and Care Issues
  • 3:30 PM – 4:45 PM
    The Great Debate: Graft Versus Host Disease (GVHD) Prophylaxis Strategies (Encore)
  • 5:00 PM – 7:30 PM
    E-Poster Reception - Completed & Late Breaking Research + Trainee Top Ten
  • 6:30 PM – 7:30 PM
    Non-CE Symposia: LUNSUMIO (mosunetuzumab-axgb): A Novel, First-in-class, T-cell Engaging Bispecific Antibody in 3L+ Follicular Lymphoma
  • 6:30 PM – 7:30 PM
    Non-CE Symposia: Treatment and management of myelofibrosis
  • 6:30 PM – 8:00 PM
    IRC Reception (Invite Only)